VRX, HLF, REGN, ACT And BMY, Pushing Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 119 points (0.7%) at 16,493 as of Wednesday, Jan. 15, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,941 issues advancing vs. 990 declining with 158 unchanged.

The Drugs industry currently sits up 0.6% versus the S&P 500, which is up 0.5%. On the negative front, top decliners within the industry include Alnylam Pharmaceuticals ( ALNY), down 6.3%, Isis Pharmaceuticals ( ISIS), down 4.5%, Incyte ( INCY), down 3.7%, Forest Laboratories ( FRX), down 0.8% and Biogen Idec ( BIIB), down 0.8%. Top gainers within the industry include Intercept Pharmaceuticals ( ICPT), up -1.6%, Pfizer ( PFE), up 0.9% and Amgen ( AMGN), up 0.3%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Valeant Pharmaceuticals International ( VRX) is one of the companies pushing the Drugs industry lower today. As of noon trading, Valeant Pharmaceuticals International is down $1.90 (-1.4%) to $133.12 on average volume. Thus far, 515,544 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $132.82-$136.20 after having opened the day at $135.08 as compared to the previous trading day's close of $135.01.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $43.5 billion and is part of the health care sector. Shares are up 15.0% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk. Get the full Valeant Pharmaceuticals International Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

4. As of noon trading, Herbalife ( HLF) is down $2.47 (-3.1%) to $78.32 on average volume. Thus far, 1.2 million shares of Herbalife exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $77.25-$80.74 after having opened the day at $80.49 as compared to the previous trading day's close of $80.79.

Herbalife Ltd., through its subsidiaries, produces and distributes weight management, healthy meals and snacks, sports and fitness, energy and targeted nutritional products, and personal care products worldwide. Herbalife has a market cap of $8.1 billion and is part of the consumer goods sector. The company has a P/E ratio of 16.5, below the S&P 500 P/E ratio of 17.7. Shares are up 2.7% year-to-date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Herbalife a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Herbalife as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, increase in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Herbalife Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, Regeneron Pharmaceuticals ( REGN) is down $11.29 (-3.8%) to $289.03 on heavy volume. Thus far, 565,772 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 749,200 shares. The stock has ranged in price between $286.02-$295.88 after having opened the day at $291.97 as compared to the previous trading day's close of $300.32.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $26.2 billion and is part of the health care sector. The company has a P/E ratio of 37.6, above the S&P 500 P/E ratio of 17.7. Shares are up 9.1% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Actavis ( ACT) is down $2.49 (-1.3%) to $183.51 on average volume. Thus far, 519,367 shares of Actavis exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $183.20-$186.34 after having opened the day at $186.00 as compared to the previous trading day's close of $186.00.

Actavis plc, an integrated specialty pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally. Actavis has a market cap of $31.6 billion and is part of the health care sector. Shares are up 10.7% year-to-date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Actavis a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Actavis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Bristol-Myers Squibb Company ( BMY) is down $0.49 (-0.9%) to $55.19 on light volume. Thus far, 2.7 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 7.4 million shares. The stock has ranged in price between $55.15-$55.72 after having opened the day at $55.70 as compared to the previous trading day's close of $55.68.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $91.3 billion and is part of the health care sector. The company has a P/E ratio of 33.4, above the S&P 500 P/E ratio of 17.7. Shares are up 4.8% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, solid stock price performance, impressive record of earnings per share growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Bristol-Myers Squibb Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash